Do you want to read an article? Please log in or register.
Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients
Rheumatoid Arthritis
Related content
Rheumatoid ArthritisFurther Publications Rheumatology
HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA
Arthritis Res Ther
Rigby W, Buckner JH, Louis Bridges S Jr, Nys M, Gao S, Polinsky M, Ray N, Bykerk V
doi: 10.1186/s13075-021-02607-7
Rheumatoid Arthritis
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
Clin Rheumatol.
van der Heijde D, Durez P, Schett G, Naredo E, Østergaard M, Meszaros G, De Leonardis F, de la Torre I, López-Romero P, Schlichting D, Nantz E, Fleischmann R
doi: 10.1007/s10067-018-4221-0.
Rheumatoid Arthritis
Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN
Arthritis Res Ther.
López-Romero P, Martinez-Gamboa L, Bang H, de la Torre I, Holzkämper T, Feist E
doi: 10.1186/s13075-020-02284-y.
Rheumatoid Arthritis
Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab
Ann Rheum Dis.
Shafran IH, Alasti F, Smolen JS, Aletaha D
doi: 10.1136/annrheumdis-2019-215987.
Systemic Lupus Erythematosus
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus
Arthritis Rheumatol.
Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A
doi: 10.1002/art.41253.
COMMENTED
Rheumatoid Arthritis
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
★ 2
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Arthritis Res Ther.
Lukas C, Mary J, Debandt M, Daïen C, Morel J, Cantagrel A, Fautrel B, Combe B
doi: 10.1186/s13075-019-2020-x.
Rheumatoid Arthritis
The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register
Arthritis Rheumatol.
Gwinnutt JM, Symmons DP, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SM
doi: 10.1002/art.40090.
Rheumatoid Arthritis
Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
Ann Rheum Dis.
Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A
doi: 10.1136/annrheumdis-2018-213502.
Rheumatoid Arthritis
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study
Arthritis Res Ther
Drobinski PJ, Bay-Jensen AC, Karsdal MA, Sardar S, Siebuhr AS
doi: 10.1186/s13075-020-02378-7